Skip to content
Home
Science
Our Approach
Oncology
Arthritis
Inflammatory Bowel Disease
Company
About Us
Our Name
Our Team
News
In the News
Press Releases
Publications
Contact
Menu
Home
Science
Our Approach
Oncology
Arthritis
Inflammatory Bowel Disease
Company
About Us
Our Name
Our Team
News
In the News
Press Releases
Publications
Contact
Albatroz Therapeutics
In the News
11/07/2023
Albatroz Co-Founder and CEO, Dr. Fredric Bard is spotlighted by A*STAR – Agency for Science, Technology and Research for his insights as a scientist-entrepreneur
10/18/2023
Albatroz Named One of Six Companies Leading Singapore’s Biotech Scene
10/10/2023
Albatroz Featured in the Novo Nordisk Singapore Partnering Day 2023
View All
Albatroz Therapeutics
Press Releases
09/04/2024
Albatroz Therapeutics Soars into Johnson & Johnson Innovation – JLABS Singapore
04/25/2023
Albatroz Therapeutics Secure $3 Million to Develop First-ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation
03/19/2023
Amgen and NSG Biolabs Announce Albatroz Therapeutics as Winner of First Amgen Golden Ticket in Singapore
View All
Publications
ER-resident oxidoreductases are glycosylated and trafficked to the cell surface to promote matrix degradation by tumour cells.
Nat. Cell Biol. 22(11) 1371–1381 (2020). DOI: 10.1038/s41556-020-00590-w
Src activates retrograde membrane traffic through phosphorylation of GBF1.
eLife. 10:268678 (2021). DOI: 10.7554/eLife.68678
The GalNAc-T Activation (GALA) Pathway: Drivers and markers.
PLoS One. 19;14(3):e0214118 (2019). DOI: 10.1371/journal.pone.0214118
Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis.
Cancer Cell. 13;32(5):639-653.e6 (2017). DOI: 10.1016/j.ccell.2017.10.001
Cracking the glycome encoder: signaling, trafficking, and glycosylation.
Trends Cell Biol. 26, 379–388 (2016). DOI: 10.1016/j.tcb.2015.12.004
Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives.
Biochim Biophys Acta. 1860(8):1623-39 (2016). DOI: 10.1016/j.bbagen.2016.03.008
ERK8 is a negative regulator of O-GalNAc glycosylation and cell migration.
eLife 3, e01828 (2014). DOI: 10.7554/eLife.01828
Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness.
Proc. Natl Acad. Sci. USA 110, E3152–E3161 (2013). DOI: 10.1073/pnas.1305269110
Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes.
J. Cell Biol. 189(5):843-858 (2010). DOI: 10.1083/jcb.201003055
GALA drives arthritis and cartilage degradation by synovial fibroblasts.
(manuscript in preparation).